As SLC4A2 is correlated with the poor differentiation and prognosis of the ESCC, hepatocellular carcinoma [123], gastric cells [130], and colon cancer [129], it is considered an underlying target for diagnosing and treating these diseases. This evidence concerns the gene SLC4A2 and hepatocellular carcinoma.